Vilanterol

{{Short description|Asthma drug – beta-adrenergic agonist}}

{{Drugbox

| drug_name =

| IUPAC_name = 4-{(1R)-2-[(6-{2-[(2,6-Dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol

| image = Vilanterol.svg

| width = 220

| alt =

| caption =

| tradename =

| Drugs.com =

| MedlinePlus =

| pregnancy_AU = B3

| pregnancy_US =

| pregnancy_category =

| licence_EU = yes

| legal_AU = S4

| legal_CA =

| legal_UK = POM

| legal_US = Rx-only

| legal_status = Rx-only

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number = 503068-34-6

| ATCvet =

| ATC_prefix = R03

| ATC_suffix = AK10

| ATC_supplemental = (+fluticasone)
{{ATC|R03|AL03}} (+umeclidinium)

| PubChem = 10184665

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 028LZY775B

| ChemSpiderID = 8360167

| IUPHAR_ligand = 7353

| DrugBank =

| ChEBI = 75037

| ChEMBL = 1198857

| KEGG = D09696

| C = 24

| H = 33

| Cl = 2

| N = 1

| O = 5

| smiles = c1cc(c(c(c1)Cl)COCCOCCCCCCNC[C@@H](c2ccc(c(c2)CO)O)O)Cl

| StdInChI = 1S/C24H33Cl2NO5/c25-21-6-5-7-22(26)20(21)17-32-13-12-31-11-4-2-1-3-10-27-15-24(30)18-8-9-23(29)19(14-18)16-28/h5-9,14,24,27-30H,1-4,10-13,15-17H2/t24-/m0/s1

| StdInChIKey = DAFYYTQWSAWIGS-DEOSSOPVSA-N

}}

Vilanterol is an ultra-long-acting β₂-adrenoceptor agonist which was approved in May 2013 in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD).{{cite web|title=FDA approves Breo Ellipta to treat chronic obstructive pulmonary disease|website=Food and Drug Administration |url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm351664.htm|archive-url=https://web.archive.org/web/20130607063526/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm351664.htm|url-status=dead|archive-date=June 7, 2013|access-date=10 May 2013}}{{cite journal | vauthors = McKeage K | title = Fluticasone furoate/vilanterol: a review of its use in chronic obstructive pulmonary disease | journal = Drugs | volume = 74 | issue = 13 | pages = 1509–22 | date = September 2014 | pmid = 25074268 | doi = 10.1007/s40265-014-0269-6 | s2cid = 29379731 }} The combination is also approved for the treatment of asthma in Canada, Europe, Japan{{cite journal | vauthors = Syed YY | title = Fluticasone furoate/vilanterol: a review of its use in patients with asthma | journal = Drugs | volume = 75 | issue = 4 | pages = 407–18 | date = March 2015 | pmid = 25648266 | doi = 10.1007/s40265-015-0354-5 | s2cid = 24563680 }} and New Zealand.{{Cite web|url=https://www.healthnavigator.org.nz/medicines/f/fluticasone-plus-vilanterol/|title=Fluticasone and vilanterol | Health Navigator NZ|first=Site designed and developed by bka interactive ltd, Auckland, New|last=Zealand (www.bka.co.nz)|website=Health Navigator New Zealand|date=22 June 2019 }}

Vilanterol is available in following combinations:

• with inhaled corticosteroid fluticasone furoate—fluticasone furoate/vilanterol (trade names Breo Ellipta (U.S., NZ), Relvar Ellipta (EU, RU, JPN))
• with muscarinic antagonist umeclidinium bromide—umeclidinium bromide/vilanterol (trade name Anoro Ellipta)
• with inhaled corticosteroid fluticasone furoate and muscarinic antagonist umeclidinium bromide—fluticasone furoate/umeclidinium bromide/vilanterol (trade name Trelegy Ellipta)